Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of GHD (growth hormone deficiency) as defined by two different GH (growth hormone) stimulation tests, peak GH level below or equal to 7.0 ng/ml. For children with three or more pituitary hormone deficiencies only one GH stimulation test will be needed. If in accordance with country specific practice, growth hormone deficiency can be defined by only one GH stimulation test, peak GH level below or equal to 7.0 ng/ml.~* Pre-pubertal children at screening. Boys: Tanner stage 1 and age above or equal to 6 years and below 13 years. Girls: Tanner stage 1 and age above or equal to 6 years and below 12 years~* Body weight above or equal to 16.0 kg and below or equal to 50.0 kg~* Stable GH replacement treatment for at least 3 months~Exclusion Criteria:~* History or presence of malignancy~* Overt diabetes mellitus (fasting blood glucose above or equal to 7.0 mmol/l)

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- NNC0195-0092 (somapacitan) (Type: EXPERIMENTAL): None
- Norditropin® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).